Truelson Katherine A, Brennan-Krohn Thea, Smith Kenneth P, Kirby James E
Boston University, Boston, MA, USA.
Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Diagn Microbiol Infect Dis. 2018 Oct;92(2):168-171. doi: 10.1016/j.diagmicrobio.2018.05.018. Epub 2018 May 29.
We evaluated the in vitro activity of apramycin against clinical strains of vancomycin-intermediate and methicillin-resistant and -susceptible Staphylococcus aureus. Apramycin demonstrated an MIC/MIC of 8/16 μg/mL. No strains had an MIC above the epidemiological cutoff value of 32 μg/mL, suggesting apramycin resistance mechanisms are rare in this strain population. The mounting evidence for broad-spectrum in vitro activity of apramycin against S. aureus and other bacterial species suggests that further exploration of apramycin or derivatives as repurposed human therapeutics is warranted.
我们评估了阿普拉霉素对万古霉素中介型、耐甲氧西林和甲氧西林敏感的金黄色葡萄球菌临床菌株的体外活性。阿普拉霉素的最低抑菌浓度/最低杀菌浓度为8/16μg/mL。没有菌株的最低抑菌浓度高于32μg/mL的流行病学临界值,这表明在该菌株群体中阿普拉霉素耐药机制很少见。越来越多的证据表明阿普拉霉素对金黄色葡萄球菌和其他细菌具有广谱体外活性,这表明有必要进一步探索将阿普拉霉素或其衍生物用作重新利用的人类治疗药物。